Monthly Archives: June 2020

Sernova Highlights Positive Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions – TheNewswire.ca

Posted: June 18, 2020 at 7:49 pm

LONDON, ONTARIO - TheNewswire - June 18, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, highlights positive results from its submitted abstract entitled "Clinical Validation of the Implanted Pre-Vascularized Cell Pouch(TM) as a Viable, Safe Site for Diabetes Cell Therapy," selected for presentation at the American Diabetes Association's (ADA) 80th Scientific Sessions held virtually June 12-16, 2020.

"Sernova was honored that its abstract was selected under peer review to be presented at the prestigious ADA Scientific Sessions. The findings reported in diabetic patients, demonstrate that human donor islets transplanted into Sernova's Cell Pouch consistently demonstrate islet survival and the ability to produce the array of hormones required to treat diabetes," said Dr. Philip Toleikis, President and CEO of Sernova.

The following provides the background of our scientific presentation:

- Cellular transplantation therapy has the potential to treat severe, chronic diseases such as Type 1 Diabetes (T1D). The transplantation site and device approach are major factors influencing successful clinical outcomes;

- With new cell-based emerging technologies, there continues to be a need to find a safe, retrievable, biologically compatible device for cellular transplantation and we believe Sernova's Cell Pouch System may provide such a solution;

- The transplantation of insulin-producing islets is a cellular replacement therapy for severe T1D in patients who experience life-threatening severe hypoglycemia unawareness events;

- In this clinical indication, Sernova has conducted a physician sponsored first-in-human study in Canada and currently has an ongoing company-sponsored Phase I/II human clinical study at the University of Chicago. In both clinical studies, patients with T1D were implanted with both sentinel (small devices removed to assess cell survival) and larger therapeutic devices, anywhere between 1 to 6 months;

- After being placed on immunosuppression, islets were isolated from donor pancreata and transplanted into patients within the device chambers. When possible, a pre-transplant sample of islets was saved for comparison to post-explant Cell Pouch islets; and

- Cell Pouches were explanted from patients, anywhere between 14-90 days post-transplant. The Cell Pouches were prepared, and sections were stained and imaged, and then reviewed by an independent clinical pathologist to assess the transplanted tissue for micro-vessel formation and vascularization; the presence of islets with insulin, C-peptide, and other endocrine hormones (such as glucagon and somatostatin); and exocrine tissue (such as pancreatic ductal tissue).

The data presented clinically demonstrate that the vascularized Cell Pouch provides a consistently safe and biologically suitable, retrievable environment for the transplantation and survival of functional islets. Specific findings based on a detailed histopathological analysis of nine Sernova Cell Pouches explanted from patients with T1D diabetes include:

- Explanted Cell Pouches show abundant, viable, organized islet cells intimately associated with blood vessels within a natural collagen matrix following transplantation without obvious rejection or infection;

- 100% showed present or abundant blood vessels;

- 89% showed present or abundant insulin;

- 78% showed present or abundant endocrine cells;

- 100% showed present or abundant ductal tissue;

- Islet cells required to control diabetes within the Cell Pouches consistently express insulin and other endocrine hormones, such as glucagon, somatostatin, and C-peptide, when identified histologically;

- Pre-transplant islet samples that show strongly expressed insulin, as well as other endocrine markers, were similarly identified in the explanted Cell Pouches following transplant; and

- The amount of islet/exocrine tissue within pre-transplanted samples was similar to that found in the Cell Pouch following transplantation.

In summary, the transplanted samples, when explanted and examined, demonstrate healthy, surviving islets with multiple cell types within the islets capable of producing the hormones that control blood sugar levels when housed in the vascularized tissue matrix of the Cell Pouch. Exocrine ductal tissue, when transplanted, also survived. The findings demonstrate the pre-transplant samples are consistent with the histology observed upon explantation of the Cell Pouch at different time points. These clinical findings demonstrate that the Cell Pouch is a viable, safe site for diabetes cell therapy.

Dr. Toleikis said, "The positive results reported in patients in this diabetes indication, implanted with Sernova's Cell Pouch and transplanted with islets, continue to validate our Cell Pouch System cell therapy therapeutics approach. Within the emerging cell therapy field, Sernova, with its advancing cell therapies including locally immune protected stem cell-derived cells, continues to position itself as a leader in the development of a 'functional cure' for all patients with diabetes and other chronic diseases."

A recording of Sernova's ADA Scientific Session presentation is available at http://www.sernova.com/updates.

ABOUT SERNOVA'S CLINICAL TRIAL

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial at the University of Chicago to assess the safety and tolerability of islet transplantation into the company's patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova's clinical trial are incapable of producing c-peptide, a biomarker for insulin produced by islet cells.

Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, are transplanted into the Cell Pouch.

A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made with regard to the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further followed for one year to assess longer-term safety and efficacy.

For more information on this clinical trial, please visit http://www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit http://www.pwitkowski.org/sernova.

ABOUT SERNOVA'S CELL POUCH SYSTEM

The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago.

ABOUT SERNOVA CORP.

Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit http://www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dominic Gray

Sernova Corp.

Tel: (519) 858-5126

dominic.gray@sernova.com

http://www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors could include, but are not limited to, the company's ability to secure additional financing and licensing arrangements on reasonable terms, or at all; ability to conduct all required preclinical and clinical studies for the company's Cell Pouch System and/or related technologies, including the timing and results of those trials; ability to obtain all necessary regulatory approvals, or on a timely basis; ability to in-license additional complementary technologies; ability to execute its business strategy and successfully compete in the market; and the inherent risks associated with the development of biotechnology combination products generally. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company's quarterly and annual filings available on http://www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Go here to read the rest:
Sernova Highlights Positive Results Presented at the American Diabetes Association's Virtual 80th Scientific Sessions - TheNewswire.ca

Posted in Diabetes | Comments Off on Sernova Highlights Positive Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions – TheNewswire.ca

People with diabetes at higher risk of bone fractures – Diabetes.co.uk

Posted: June 18, 2020 at 7:49 pm

Bone health among those with diabetes could be under threat as new research shows the condition increases the risk of fractures.

A study, carried out by the University of Sheffield, found that people who have either type 1 or type 2 diabetes are at a greater risk of suffering from a hip fracture, or a similar injury.

The risk is larger among those with type 1 diabetes than people with type 2 diabetes, although this largely depends on how long the person has had the condition, researchers said.

Lead researcher Dr Tatiane Vilaca, from the University of Sheffields Mellanby Centre for Bone Research, said: Diabetes can cause a number of well-known complications including kidney problems, loss of eyesight, problems with your feet and nerve damage. However, until now many people with diabetes and their doctors are unaware that they are also at greater risk of bone fractures.

We need to raise awareness about the greater risk people with diabetes face to help them to prevent fractures. For example, preventing falls can reduce their risk of fracture.

Fractures can be very serious, especially in older people. Hip fractures are the most severe as they cause such high disability. Around 76,000 people in the UK suffer a hip fracture every year and it is thought as many as 20 per cent of people will die within a year of the fracture. Many others dont fully regain mobility, and for many people it can cause a loss of independence.

Read more on this topic:

Professor Richard Eastell, Professor of Bone Metabolism and Director of the University of Sheffields Mellanby Centre for Bone Research, said the findings highlights the urgent need for healthcare professionals to focus more on bone health among those with diabetes.

He added: We hope that by raising awareness about the greater risk people with diabetes face, bone density and bone strength will become something that doctors assess routinely in patients with the condition in the same way they do currently for other well-known complications.

The research was a collaboration with the University of California and has been published in the Bone journal.

Dr Steven Cummings, from Sutter Health, California, said: Patients with diabetes and the doctors who care for them should be aware of the increased risk of fractures. Patients are encouraged to ask their doctors what to do about that risk, and doctors should assess the risk and consider treatment to reduce that risk.

Continued here:
People with diabetes at higher risk of bone fractures - Diabetes.co.uk

Posted in Diabetes | Comments Off on People with diabetes at higher risk of bone fractures – Diabetes.co.uk

Genetics and Pharmacology | YourHub – The Know

Posted: June 17, 2020 at 11:47 pm

Ever had a bad experience with a prescription?

Ever thought it was an allergic reaction to a medication?

In 2017 I had a significant abdominal surgery that required me to take pain medication, anti-inflammatories, and antibiotics. The surgery was supposed to help with a significant abdominal umbilical hernia. It occurred on a Wednesday, and by Monday, I was having a significant reaction to the pain medication, where my FACE went NUMB. Talk about scary.

Leading up to the surgery, I had taken part in 2 appointments where I discussed previous bad reactions to the pain medication and talked about my concerns. They told me it was a necessary evil in this case so that I could sleep. The morning of surgery, after long discussion with the anesthesiologist, He asked if I had testing done to look at my response to different drugs. At that time, I didnt even know that was a thing that could be done.

The news media and medical media lately has talked a lot about epigenetics and epigenomics and we are starting to hear about pharmacogenetics. Pharmacogenetics can be done through DNA testing to specifically look at your genetics and how they might react to specific types of drugs. They can allow for better dosing, better drug choice so there is less guess work, and overall better outcomes. Pharmacogenetics can also help in looking at how some people may become addicted and others not to things like marijuana, which the Prop 64 group in Colorado would have us believe is not possible.

Pharmacogenetics can also let us know when it might be time to change a drug, because the epigenetics/epigenomics, or the environmental factors that cause the genes to change may have been affected over long-term use of specific drugs. These drugs can be related to addiction treatment, pain management, mental health disorders (bipolar, schizophrenia, depression), autoimmune logical drugs including chemotherapy.

Along the line of epigenetics/epigenomics, there is a specific testing that can be done that supports your DNA sections. It looks at what will optimally support your health, and with that information we can create a supplement that is SPECIFIC to you. Repeating the test about 6 months after initial testing and consuming of those supplements is recommended due to the changes you could potentially make. Then every year.

Why would you need a DNA-specific supplement? Colorado has one of the highest levels of radiation exposure in the continental U.S. Specifically, we have a lot of naturally occurring uranium and radon. Both of those are known carcinogens. Also, think about how much and what type of sunscreen you apply every year in Colorado while enjoying the outdoor lifestyle you love. Chemical barriers are more likely to interact with the radiation from the sun to create mutation of cells. It starts at the skin level, but quickly spreads to the body as the skin is an organ that ABSORBS things you put on it.

If you have questions about how DNA testing can improve your health, life and longevity, dont hesitate to reach out!

References:

*https://dnalife.academy/dna-health/

*Recent developments in genetic/genomic medicine, Rachel H. Horton and Anneke M. Lucassen, Clin Sci (Lond). 2019 Mar 15; 133(5): 697708.Published online 2019 Mar 5. Prepublished online 2019 Feb 27. doi: 10.1042/CS20180436

*Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry; Azmeraw T. Amare,1 Klaus Oliver Schubert,1,2 and Bernhard T. Baune1; EPMA J. 2017 Sep; 8(3): 211227.Published online 2017 Sep 5. doi: 10.1007/s13167-017-0112-8*Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants; Ramn Cacabelos,1,2,* Luca Fernndez-Novoa,1,2 Roco Martnez-Bouza,1,2 Adam McKay,1,2 Juan C. Carril,1,2 Valter Lombardi,1,2 Lola Corzo,1,2 Ivn Carrera,1,2 Ivn Tellado,1,2 Laura Nebril,1,2 Margarita Alcaraz,1,2 Susana Rodrguez,1,2 ngela Casas,1,2 Vernica Couceiro,1,2 and Antn lvarez1,2Pharmaceuticals (Basel). 2010 Oct; 3(10): 30403100.Published online 2010 Sep 29. doi: 10.3390/ph3103040*Some observations on the role of environment and genetics in behaviour of wild and domestic forms of Sus scrofa (European wild boars and domestic pigs)S Robert, J Dancosse, A Dallaire Applied Animal Behaviour Science, 1987 Elsevier

Read this article:
Genetics and Pharmacology | YourHub - The Know

Posted in Epigenetics | Comments Off on Genetics and Pharmacology | YourHub – The Know

Lexogen and OnRamp Bioinformatics partner to provide differential gene expression data analysis and interpretation for QuantSeq 3′ mRNA-Seq users – PR…

Posted: June 17, 2020 at 11:47 pm

VIENNA and SAN DIEGO, June 17, 2020 /PRNewswire/ -- Lexogen, a transcriptomics and Next Generation Sequencing company, and OnRamp Bioinformatics, a provider of cloud-based genomic analysis and collaboration tools, announced availability for the QuantSeq 3' mRNA-Seq data analysis pipeline on ROSALIND, the globally recognized discovery platform for scientists and researchers. The partnership enhances QuantSeq 3' mRNA-Seq data analysis with ROSALIND's visual data exploration and deep pathway interpretation with more than 50 knowledge bases.

Lexogen's QuantSeq 3' mRNA-Seq is a straightforward, fast, and cost-efficient method for library preparation. It has been widely used for expression profiling analysis and is currently featured in more than 470 publications. "QuantSeq is a well-established library preparation kit, validated by researchers who have used it for a broad range of applications. We are continuously enhancing the workflow based on the user feedback, and offering a complete solution including data analysis has always been top priority", said Dalia Daujotyte, Chief Commercial Officer at Lexogen.

As a platform for scientists, ROSALIND empowers QuantSeq 3' customers to analyze, interpret and collaborate globally on differential gene expression analysis without the need for specialized bioinformatics or programming skills. "Through our collaborations, it is our goal to provide full transcriptome analysis solutions vetted by experts in their fields. Access to QuantSeq data processing on ROSALIND not only gives an opportunity to an in-depth gene expression analysis, but also enables collaboration and multi-omics work without leaving the environment", added Daujotyte.

"QuantSeq 3' has been a game-changer for our biotech and pharma clients adopting RNA-seq, with the compelling economics to support high volume and the ability to assess the whole transcriptome," said Tim Wesselman, CEO of OnRamp Bio. "With ROSALIND, QuantSeq users of every skill level are empowered to visually explore same day results, save valuable time and restore the thrill of discovery," added Wesselman.

The usage of ROSALIND for QuantSeq data analysis and interpretation will be demonstrated in the GenomeWeb webinar "Integration of 3'mRNA-Seq and ChIP-Seq Datasets to Disentangle Redundant Epigenetic Regulatory Mechanisms", taking place on June 18, 2020. Register here: bit.ly/2AN9URF

About Lexogen

Established in 2007, Lexogen is a transcriptomics and Next-Generation Sequencing company, focusing on the development of innovative methods for RNA analysis. Its portfolio includes multiple innovative and well-established protocols for RNA sequencing sample preparation, external RNA spike-in controls, as well as bioinformatics tools and sequencing services. Lexogen is a privately held company, headquartered in Vienna, Austria with a subsidiary in New Hampshire, US.

To learn more, visit http://www.lexogen.com and follow @lexogen.

Contact person:Jekaterina AleksejevaSenior Marketing ManagerTel.: +43 699 1023 8946Email: jekaterina.aleksejeva@lexogen.com

About OnRamp Bioinformatics

OnRamp BioInformatics is the San Diego genomics software company that develops and maintains the ROSALIND discovery and collaboration platform designed for biologists and researchers. ROSALIND is globally deployed and trusted by top pharma, biotech and research institutions as the leading cloud platform for transcriptomics and epigenetics with comprehensive QC, deep pathway interpretation, advanced multi-omic meta-analyses and collaborative gene signatures.

To learn more, visit http://www.onramp.bio and follow us on Twitter or LinkedIn (@OnRampBio).

Contact person:Cassandra ElwellInvestor Relations & Communications OfficerTel.: +1 855 766 7267 ext. 708Email: cassandra@onramp.bio

Logo - https://mma.prnewswire.com/media/472869/Lexogen_logo_Logo.jpg Logo - https://mma.prnewswire.com/media/1192411/Lexogen_Logo.jpg

HOME

SOURCE Lexogen

The rest is here:
Lexogen and OnRamp Bioinformatics partner to provide differential gene expression data analysis and interpretation for QuantSeq 3' mRNA-Seq users - PR...

Posted in Epigenetics | Comments Off on Lexogen and OnRamp Bioinformatics partner to provide differential gene expression data analysis and interpretation for QuantSeq 3′ mRNA-Seq users – PR…

Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters – BioSpace

Posted: June 17, 2020 at 11:46 pm

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Cellics Therapeutics, Inc.. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters, entitled Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity, based on research conducted by its founder, Liangfang Zhang, Ph.D.http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c02278

As new information about COVID-19 continues to emerge almost on a daily basis, the virus has already demonstrated its ability to mutate and became more infectious, raising doubts about the viability of an effective vaccine and potential future therapies. A therapy that is agnostic to future mutations and has the potential to address future novel viral pandemics is extremely attractive. Treatments that target the affected host cell rather than the infectious agent may offer an opportunity to address future mutations and novel viral outbreaks.

The published study was initiated to evaluate the potential of nanosponges derived from human cells as a therapeutic for the treatment of COVID-19. The study was a collaborative effort between the Department of NanoEngineering at the University of California San Diego Jacobs School of Engineering and the Department of Microbiology and National Emerging Infectious Diseases Laboratories at the Boston University School of Medicine.

Nanosponges derived from macrophages and human pulmonary epithelial cells were tested as it is understood that SARS-CoV-2 enters the cells via known receptors (ACE-2 and CD147) and maybe other unknown receptors. Macrophage and pulmonary epithelial nanosponges were incubated with SARS-CoV-2 infected cells to assess if nanosponges are able to neutralize live SARS-CoV-2 virus. Both macrophage and pulmonary epithelial cell nanosponges demonstrated significant neutralization of SARS-CoV-2 infectivity after two hours of incubation in a concentration dependent manner.

This data represents a validation of the nanosponge platform and our approach of identifying the affected host cell to develop nanosponges as a therapy, said Steve Chen, MD, President and Chief Medical Officer, Cellics Therapeutics. The nanosponge technology allows the therapy to be mutation and virulence factor agnostic, making it a potential universal anti-viral agent for future viral outbreaks. Previous work has shown that macrophage nanosponges neutralized inflammatory cytokines, which are involved in the cytokine storms described in COVID-19 patients. We are particularly excited with the macrophage nanosponges data as a potential therapy to neutralize both the viral activity and the downstream complications associated with COVID-19. We look forward to further validation studies and mapping out a potential path forward to deliver this promising therapy to patients.

Cellics holds exclusive global rights for the development and commercialization of red blood cell and white blood cell nanosponges, including macrophage nanosponges for treatment of various diseases from the University of California, San Diego. Currently, Cellics is developing macrophage nanosponges for the treatment of sepsis.

About Nanosponge Platform Technology

Our proprietary platform technology strips cell membranes of their intracellular contents and allows us to create nanosponges from these membranes to be leveraged as a therapeutic product (Nanosponge Technology). These nanosponges are designed to counteract diverse disease pathologies by acting as biomimetic decoys to sequester and neutralize biological molecules that would otherwise attack host cells. Examples of such harmful agents include toxins, inflammatory cytokines and viruses. The cell membrane forming the outer layer of the nanosponges is selected according to the disease pathology, specifically which host cells are under attack. Nanosponges leverage the natural bioactivity of human cell membrane receptors for therapeutic efficacy. With the advantage of their small size and large quantity, nanosponges outcompete host cells in binding and sequestering biological molecules.

Product development currently emphasizes the use of nanosponges made of human red blood cell membrane and white blood cell membrane for the treatment of bacterial infections and inflammatory diseases. A similar working principle can be applied with membranes of other cell types, making nanosponges suitable for large and diverse disease areas. We have achieved proof of concept in animal models in a range of disease areas.

About Cellics

Cellics Therapeutics, Inc. (Cellics or Company) is a privately held development stage pharmaceutical company founded in 2014 by UC San Diego professor Liangfang Zhang based on his award-winning Nanosponge Technology. Cellics was created with the goal of applying the Nanosponge Technology to treat and prevent diseases.

Cellics is committed to saving lives and improving patients health using innovative biomimetic nanomedicines. The Companys primary focus at this time is on autoimmune and inflammatory diseases and difficult-to-treat infectious diseases. Cellics also aims to develop best-in-class vaccines for various diseases. The Company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of MRSA pneumonia.

It is the passion and goal of Cellics to use advanced technology to help patients live healthier and longer lives. Visit us at cellics.com.

About UC San Diego Jacobs School of Engineering

The Jacobs School of Engineering at the University of California San Diego offers excellence at scale in research, education, public service, and technology transfer. The Jacobs School ranks first among all public engineering schools for research expenditures per faculty member. These entrepreneurial faculty lead teams that work across disciplines and industries to tackle the toughest challenges that no lab, department or company can handle alone. At the Jacobs School of Engineering, we make bold possible. Visit us athttp://jacobsschool.ucsd.edu/

Forward-looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, any one of which may cause actual results to be materially different from these forward-looking statements. These factors include, without limitation, the ability to duplicate the study results in future studies; the timing and success of our development of CTI-005, CTI-008, CTI-105, CTI-108, and other pipeline candidates; the ability to successfully scale-up our manufacturing process; the timing, costs, conduct, and outcome of our clinical study; and the indication(s) for which our pipelines may be developed. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts

Steve Chen, MDPresident and Chief Medical OfficerCellics Therapeutics, Inc.(858) 412-6148schen@cellics.com

UC San Diego Media ContactIoana PatringenaruPublic Information RepresentativePhone: 858-822-0899ipatrin@ucsd.edu

Source: Cellics Therapeutics, Inc.

Excerpt from:
Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters - BioSpace

Posted in Nano medicine | Comments Off on Cellics Therapeutics Announces the Publication of Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity in Nano Letters – BioSpace

Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data – PRNewswire

Posted: June 17, 2020 at 11:46 pm

NEW YORK, June 17, 2020 /PRNewswire/ -- The globalNanocellulose marketis forecast to reach USD 1.08 Billion by 2027, according to a new report by Reports and Data. The market is seeing an expanded interest from the composites sector owing to its critical characteristics, including biodegradability, non-toxicity, and sustainability, along with thixotropic Nanocellulose properties. However, volatile prices of raw materials arising necessity for exploring and adopting other content as a substitute to reduce the overall cost of the operation will be hampering the demand for the market.

Cosmetics would have substantial potential for Nanocellulose across the forecast period. It is used as a synthetic covering agent for fingers, eyes, eyebrows, or eyelashes in cosmetics. The product also provides antioxidant properties and is now used in products for sun care. It is also used for wound dressings in the surgical profession and regenerative medicine. Other uses include pharmaceuticals, tobacco filter additives, computer components, electronic displays, condensers, lithium battery films, lightweight body armor, loudspeaker membranes, and ballistic glass. However, low awareness about product use and high prices may, in the coming years, somehow hamper the demand. Nano fibrillated cellulose held the highest share in the overall market in 2019.

Request free sample of this research report at: https://www.reportsanddata.com/sample-enquiry-form/3207

They possess exceptional properties, including superior strength, lightweight, transparency, and rigidity, among others, which makes them viable for many commercial applications across composites, oil & gas, food & beverage, automotive, aerospace, and personal care industries. Nano-fibrillated cellulose could also be a future replacement for plastic films in composite packaging due to the low oxygen permeability. The composites segment was the largest application segment in the overall market in 2019 by volume. Nowadays, composites are used widely in many applications. It is used in refurbishments as filler stuff. End-users are increasingly concerned about the application of synthetic fillers in composites and the environmental concerns associated with that application. Thus, replacing synthetic pads with natural ones like cellulose fibers will bring many positive environmental benefits as the product offers good thermal conductivity, low density, and biodegradability, owing to increasing personal care and food & beverage industries in the area. The market in the Asia Pacific region will propel the product demand over the projected period. Countries, including China, Japan, and India, have played a significant role in enhancing the nanotech profile of the region. Japan's AIST Nanocellulose Forum, for example, is focused on strengthening cooperation between industry, universities, and government.

The COVID-19 Impact:

As the COVID-19 crisis continues to intensify, producers are quickly adapting their activity and purchasing objectives to satisfy the demands of a pandemic that has limited the need for Nanocellulose in the market. A sequence of both positive and negative shocks may arise over a few months, as producers and their vendors respond to the evolving demands of customers. The export-dependent economies in several nations look weak, with an adverse global circumstance. Global Nanocellulose markets are reshaped by the effects of this pandemic, as some suppliers are either shutting down or reducing their output, due to a lack of demand from the downstream market. Although others are getting their production suspended as a precautionary step by their respective governments to prevent the spread of the virus. In certain countries, consumers based on being more regional by looking at the magnitude of the epidemic and the consequent behavior of the national authorities themselves. Under these circumstances, market conditions of the Asia Pacific regions were quite dynamic, weakening regularly, making stabilizing themselves difficult.

To identify the key trends in the industry, click on the link below:https://www.reportsanddata.com/report-detail/nanocellulose-market

Further key findings from the report suggest

Order Now: https://www.reportsanddata.com/checkout-form/3207

For the purpose of this report, Reports and Data have segmented into the global Nanocellulose market on the basis of product, distribution channel, application, and region:

Product Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Distribution Channel Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Application Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Regional Outlook (Volume, Kilo Tons; 2017-2027) (Revenue, USD Million; 2017-2027)

Browse more similar reports on Materials and Chemicalscategory by Reports And Data

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client's make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:

John WHead of Business DevelopmentReports And Data | Web: http://www.reportsanddata.com Direct Line: +1-212-710-1370E-mail: [emailprotected] LinkedIn | Twitter | Blogs

SOURCE Reports And Data

Continue reading here:
Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire

Posted in Nano medicine | Comments Off on Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data – PRNewswire

Trending News 2020 Covid-19 impact on Testosterone Replacement Therapy Market Growth Forecast by Type -2025|Pfizer,Actavis…

Posted: June 17, 2020 at 11:43 pm

The global Testosterone Replacement Therapy Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Testosterone Replacement Therapy Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Testosterone Replacement Therapy Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Testosterone Replacement Therapy Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Testosterone Replacement Therapy Market.

Leading players of the global Testosterone Replacement Therapy Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Testosterone Replacement Therapy Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Testosterone Replacement Therapy Market. It also provides useful recommendations for new as well as established players of the global Testosterone Replacement Therapy Market.

Final Testosterone Replacement Therapy Report will add the analysis of the impact of COVID-19 on this Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2343252

Major Players:

Endo InternationalAbbVieEli lillyPfizerActavis (Allergan)BayerNovartisTevaMylanUpsher-SmithFerring PharmaceuticalsKyowa KirinAcerus Pharmaceuticals

Segmentation by Product:

GelsInjectionsPatchesOthers

Segmentation by Application:

HospitalsClinicsOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2343252

the Global Testosterone Replacement Therapy Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during the 2021-2026. The report analyses the global Testosterone Replacement Therapy market, the market size and growth, as well as the major market participants.

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Testosterone Replacement Therapy Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The insight has been added in the report to provide realistic overview of the industry, consist of Testosterone Replacement Therapy manufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc., SWOT analysis, consumer preference, recent developments and trends, drivers and restrain factors, company profile, investment opportunity, demand gap analysis, forecast market size value/volume, services and product, Porters Five Models, socioeconomic factors, government regulation in Testosterone Replacement Therapy industry. Market players can use the report to peep into the future of the global Testosterone Replacement Therapy Market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

Global Testosterone Replacement Therapy Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Testosterone Replacement Therapy Market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Testosterone Replacement Therapy Market participants in the past few years to remain ahead of the competition.

Table of Contents

Report Overview:It includes major players of the global Testosterone Replacement Therapy Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Testosterone Replacement Therapy Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Testosterone Replacement Therapy Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Testosterone Replacement Therapy Market by application, it gives a study on the consumption in the global Testosterone Replacement Therapy Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Testosterone Replacement Therapy Market are profiled in this section. The analysts have provided information about their recent developments in the global Testosterone Replacement Therapy Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Testosterone Replacement Therapy Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Testosterone Replacement Therapy Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Testosterone Replacement Therapy Market.

Key Findings: This section gives a quick look at important findings of the research study.

Our industry professionals are working reluctantly to understand, assemble and timely deliver assessment on impact of COVID-19 disaster on many corporations and their clients to help them in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

See original here:
Trending News 2020 Covid-19 impact on Testosterone Replacement Therapy Market Growth Forecast by Type -2025|Pfizer,Actavis...

Posted in Testosterone Replacement Therapy | Comments Off on Trending News 2020 Covid-19 impact on Testosterone Replacement Therapy Market Growth Forecast by Type -2025|Pfizer,Actavis…

Novel oral testosterone therapy shows liver health benefits – Urology Times

Posted: June 17, 2020 at 11:43 pm

A novel lymphatically delivered oral testosterone undecanoate (Tlando) is a fixed-dose, well-tolerated, and effective treatment for hypogonadism with liver health benefits that clearly differentiate it from the potentially hepatotoxic oral methyltestosterone, reported Irwin Goldstein, MD, at the American Urological Association 2020 Virtual Experience.

This innovative product has exciting, paradigm-shifting potential for treating men with low testosterone, said Goldstein, director of Sexual Medicine at Alvarado Hospital in San Diego, California, and clinical professor of surgery at the University of California San Diego.

It offers the opportunity to provide safe, effective, and well-tolerated testosterone replacement through the oral route that is the generally preferred method for medication administration. In addition, available data indicate that it not only avoids the adverse hepatic effects that have historically limited use of oral testosterone, but it improves markers of nonalcoholic fatty liver disease [NAFLD] that is a serious and prevalent condition. Low testosterone (ie, hypogonadism) is common in males with NAFLD.

Methyltestosterone is prone to cause liver toxicity with oral ingestion because it is directly transported to the liver through the portal vein, Goldstein said. In contrast, the lymphatically delivered oral testosterone undecanoate is a nonmethylated prodrug of endogenous testosterone, found in Tlando, that avoids first-pass metabolism in the liver and enters the systemic circulation via the lymphatics.

The safety and efficacy of Tlando for treating men with low testosterone was investigated in the 1-year SOAR trial that included 210 men who received the investigational product and a control group of 105 patients treated with topical testosterone gel.

Results from SOAR showed that the oral testosterone undecanoate was associated with a significantly greater increase in free testosterone levels compared with the topical product, and it improved key mental and sexual domains, reported Goldstein, who was an investigator in SOAR and an earlier dosing study.

Safety data in the study included measurement of liver enzymes and showed that reductions were consistently achieved in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and -glutamyl transferase among men who had elevated levels of those markers of liver injury at baseline. Rates of normalization for those 4 enzymes ranged from 31% for -glutamyl transferase to 67% for alkaline phosphatase.

40% reduction in liver fat at 4 months

Additional data on the liver effects of the novel testosterone undecanoate product were obtained in a smaller separate trial of men with hypogonadism. Using the objective Magnetic Resonance Imaging Proton Density Fat Fraction technique to measure liver fat percentage, it found that after 4 months, men with NAFLD at baseline achieved an approximately 40% reduction in liver fat. In addition, more than 75% of men who entered the study with NAFLD were considered responders to the oral testosterone undecanoate based on achieving a 30% or greater reduction in the percentage of liver fat.

In addition, the percentage of patients categorized as NAFLD-free rose during the study and nearly doubled by its conclusion, increasing from 34% at baseline to reach 63% at 16 weeks.

Interestingly, the higher the baseline body mass index, the greater the reduction in liver fat achieved with Tlando treatment, and it appears that the improvement in liver fat does not appear to be explained by any decrease in body weight, Goldstein said.

Disclosures: Lipocine Inc provided funding for the study. Goldstein is on the consultant/advisory board of Lipocine Inc, does research for AbbVie Inc and Marius Pharmaceuticals LLC, is on the Clarus Therapeutics, Inc speakers bureau, and receives writing support from Endo International.

Visit link:
Novel oral testosterone therapy shows liver health benefits - Urology Times

Posted in Testosterone Replacement Therapy | Comments Off on Novel oral testosterone therapy shows liver health benefits – Urology Times

Testosterone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Posted: June 17, 2020 at 11:43 pm

New Jersey, United States,- A detailed research study on Testosterone Replacement Therapy Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Testosterone Replacement Therapy, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=208345&utm_source=COD&utm_medium=888

Leading Testosterone Replacement Therapy manufacturers/companies operating at both regional and global levels:

Testosterone Replacement Therapy Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Testosterone Replacement Therapy market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Testosterone Replacement Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Testosterone Replacement Therapy Market, By Product

Testosterone Replacement Therapy Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=208345&utm_source=COD&utm_medium=888

Testosterone Replacement Therapy Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Testosterone Replacement Therapy market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Testosterone Replacement Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Testosterone Replacement Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Testosterone Replacement Therapy Market, By Deployment Model

5.1 Overview

6 Testosterone Replacement Therapy Market, By Solution

6.1 Overview

7 Testosterone Replacement Therapy Market, By Vertical

7.1 Overview

8 Testosterone Replacement Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Testosterone Replacement Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=208345&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Labeling Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Laboratory Analytical Instruments and Consumables Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Laboratory Electronic Balance Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

See the original post here:
Testosterone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Testosterone Replacement Therapy Sales Market Growth Prospects, Revenue, Key Vendors, Growth Rate and Forecast To 2026 – Jewish Life News

Posted: June 17, 2020 at 11:43 pm

Testosterone Replacement Therapy Sales Market Overview

The Testosterone Replacement Therapy Sales market report presents a detailed evaluation of the market. The report focuses on providing a holistic overview with a forecast period of the report extending from 2018 to 2026. The Testosterone Replacement Therapy Sales market report includes analysis in terms of both quantitative and qualitative data, taking into factors such as Product pricing, Product penetration, Country GDP, movement of parent market & child markets, End application industries, etc. The report is defined by bifurcating various parts of the market into segments which provide an understanding of different aspects of the market.

The overall report is divided into the following primary sections: segments, market outlook, competitive landscape and company profiles. The segments cover various aspects of the market, from the trends that are affecting the market to major market players, in turn providing a well-rounded assessment of the market. In terms of the market outlook section, the report provides a study of the major market dynamics that are playing a substantial role in the market. The market outlook section is further categorized into sections; drivers, restraints, opportunities and challenges. The drivers and restraints cover the internal factors of the market whereas opportunities and challenges are the external factors that are affecting the market. The market outlook section also comprises Porters Five Forces analysis (which explains buyers bargaining power, suppliers bargaining power, threat of new entrants, threat of substitutes, and degree of competition in the Testosterone Replacement Therapy Sales) in addition to the market dynamics.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=241156&utm_source=JLN&utm_medium=888

Leading Testosterone Replacement Therapy Sales manufacturers/companies operating at both regional and global levels:

Testosterone Replacement Therapy Sales Market Scope Of The Report

This report offers past, present as well as future analysis and estimates for the Testosterone Replacement Therapy Sales market. The market estimates that are provided in the report are calculated through an exhaustive research methodology. The research methodology that is adopted involves multiple channels of research, chiefly primary interviews, secondary research and subject matter expert advice. The market estimates are calculated on the basis of the degree of impact of the current market dynamics along with various economic, social and political factors on the Testosterone Replacement Therapy Sales market. Both positive as well as negative changes to the market are taken into consideration for the market estimates.

Testosterone Replacement Therapy Sales Market Competitive Landscape & Company Profiles

The competitive landscape and company profile chapters of the market report are dedicated to the major players in the Testosterone Replacement Therapy Sales market. An evaluation of these market players through their product benchmarking, key developments and financial statements sheds a light into the overall market evaluation. The company profile section also includes a SWOT analysis (top three companies) of these players. In addition, the companies that are provided in this section can be customized according to the clients requirements.

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=241156&utm_source=JLN&utm_medium=888

Testosterone Replacement Therapy Sales Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Testosterone Replacement Therapy Sales market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Testosterone Replacement Therapy Sales Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Testosterone Replacement Therapy Sales Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Testosterone Replacement Therapy Sales Market, By Deployment Model

5.1 Overview

6 Testosterone Replacement Therapy Sales Market, By Solution

6.1 Overview

7 Testosterone Replacement Therapy Sales Market, By Vertical

7.1 Overview

8 Testosterone Replacement Therapy Sales Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Testosterone Replacement Therapy Sales Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=241156&utm_source=JLN&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Airport Snow Removal Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Airport Stand Equipment Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Airport Tugs Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

More:
Testosterone Replacement Therapy Sales Market Growth Prospects, Revenue, Key Vendors, Growth Rate and Forecast To 2026 - Jewish Life News

Posted in Testosterone Replacement Therapy | Comments Off on Testosterone Replacement Therapy Sales Market Growth Prospects, Revenue, Key Vendors, Growth Rate and Forecast To 2026 – Jewish Life News